Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25C | P30307 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30070191 | 1.00 | KMT2A (0.56) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL29729685 | 0.88 | KMT2A (0.62) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL845701 | 0.88 | KMT2A (0.62) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL30716618 | 0.86 | KMT2A (0.54) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL20897263 | 0.86 | KMT2A (0.54) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL8402588 | 0.81 | NLRP3 (0.48) | KMT2AALDH1A1PKMSMN1; SMN2CYP4F2 | |
| SCHEMBL31751033 | 0.81 | NLRP3 (0.48) | KMT2AALDH1A1PKMSMN1; SMN2CYP4F2 | |
| SCHEMBL10820834 | 0.80 | TDP1 (0.61) | KMT2ATDP1ATMALDH1A1HPGD | |
| SCHEMBL28332298 | 0.79 | KMT2A (0.53) | KMT2ATDP1ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL11313603 | 0.79 | MTNR1A (0.45) | KMT2AALDH1A1HPGDL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | AXIAL THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4087560-A2 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | Axial Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| CN-102134223-A | Preparation and application of novel chiral 3,4-dihydro-2-alkoxyl-6-benzyl-4-oxopyrimidine (S-DABO) human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitor | UNIV CAPITAL MEDICAL | 2011-07-27 | — | — | CN | disclosed |
| US-5929067-A | N-ACYLATING AMINE DERIVATIVE OF CAPROLACTAM COMPOUND WITH A CARBOXYLIC ACID OR DERIVATIVES TO FORM AMIDE DERIVATIVE OF CAPROLACTAM COMPOUND | NOVARTIS AG (CH) | 1999-07-27 | — | — | US | disclosed |
| EP-0810991-B1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1999-04-14 | — | — | EP | disclosed |
| EP-0810991-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | Novartis AG (CH) | 1997-12-10 | — | — | EP | disclosed |
| WO-1996026183-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131899-A1 | INHIBITORS OF MICROBIALLY INDUCED AMYLOID | SNCA, PARK7, PRNP | KMT2A 4786/4885TDP1 452/4885ATM 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.